Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Greenland Mines LtdGRML · Entity 7810 | Former Director | October 01, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Greenland Mines Ltd
Report date October 01, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Sale · Disposed 3,500 · Balance 0 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Keenova Therapeutics plc
Report date November 14, 2023 · Filed November 16, 2023
Section 16 reporting ended · disclosed 2023-11-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-14 transaction · row 1
1 source rowRow 1 · 2023-11-14 · Disposition to issuer · Disposed 23,122 · Balance 0 F1: On August 28, 2023, Mallinckrodt plc (the "Company") and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On September 20, 2023, the Company's directors presented a petition before the High Court of Ireland (the "Irish High Court") seeking the appointment of an examiner (the "Examiner") to the Company, thereby commencing examinership proceedings with respect to the Company in Ireland. F2: On October 10, 2023, the Bankruptcy Court entered an order confirming the First Amended Prepackaged Joint Chapter 11 Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates (as may be amended or supplemented from time to time in accordance with its terms, the "Plan"). On November 10, 2023, the Irish High Court made an order confirming a scheme of arrangement proposed by the Examiner that is based on and consistent in all respects with the Plan (the "Scheme"). On November 14, 2023 (the "Effective Date"), the Plan and the Scheme became effective and the Company emerged from bankruptcy. F3: On the Effective Date, all of the Company's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such Ordinary Shares, were cancelled and extinguished pursuant to the Plan and the Scheme. In connection with emergence, the reporting person ceased to be a Section 16 reporting person. This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 28, 2023, Mallinckrodt plc (the "Company") and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On September 20, 2023, the Company's directors presented a petition before the High Court of Ireland (the "Irish High Court") seeking the appointment of an examiner (the "Examiner") to the Company, thereby commencing examinership proceedings with respect to the Company in Ireland.
F2: On October 10, 2023, the Bankruptcy Court entered an order confirming the First Amended Prepackaged Joint Chapter 11 Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates (as may be amended or supplemented from time to time in accordance with its terms, the "Plan"). On November 10, 2023, the Irish High Court made an order confirming a scheme of arrangement proposed by the Examiner that is based on and consistent in all respects with the Plan (the "Scheme"). On November 14, 2023 (the "Effective Date"), the Plan and the Scheme became effective and the Company emerged from bankruptcy.
F3: On the Effective Date, all of the Company's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such Ordinary Shares, were cancelled and extinguished pursuant to the Plan and the Scheme. In connection with emergence, the reporting person ceased to be a Section 16 reporting person. This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 6, 2026 00:18 UTC | Greenland Mines Ltd GRML · Entity 7810 | SaleCommon Stock | 3,500 | $9.35 | $32,727.10 |
DisclosureSEC source: 0001213900-26-106940 · marketforms-74106.xml · nonDerivative · entry 1 El-Dada Riad Hussein · CIK 0001926018 · Former Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| June 25, 2026 Filed Jun 26, 2026 20:30 UTC | Greenland Mines Ltd GRML · Entity 7810 | SaleCommon Stock | 175,000 | $0.23 | $40,547.50 |
DisclosureSEC source: 0001213900-26-072646 · marketforms-73471.xml · nonDerivative · entry 1 El-Dada Riad Hussein · CIK 0001926018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:02 UTC | Greenland Mines Ltd KLTO · Entity 7810 | GrantCommon Stock | 350,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-024627 · marketforms-72439.xml · nonDerivative · entry 1 El-Dada Riad Hussein · CIK 0001926018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 F1 · price: The Reporting person received the shares as a grant under the company's Equity Incentive Plan. Read SEC document |
| December 10, 2025 Filed Dec 10, 2025 18:38 UTC | Greenland Mines Ltd KLTO · Entity 7810 | GrantNon-Qualified Stock Option · Derivative | 20,000 | $0.41 Strike: $0.41 | $8,200.00 |
DisclosureSEC source: 0001213900-25-119993 · marketforms-71508.xml · derivative · entry 1 El-Dada Riad Hussein · CIK 0001926018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 20,000 shares Expires 2035-01-16 F1 · derivative.exercise_date: Options are fully vested and can be exercised at any time. Read SEC document |
| August 07, 2025 Filed Aug 8, 2025 10:00 UTC | Greenland Mines Ltd KLTO · Entity 7810 | GrantNon-Qualified Stock Option · Derivative | 10,000 | $0.41 Strike: $0.41 | $4,100.00 |
DisclosureSEC source: 0001213900-25-073274 · marketforms-70267.xml · derivative · entry 1 El-Dada Riad Hussein · CIK 0001926018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 10,000 shares Expires 2035-01-16 F1 · derivative.exercise_date: Options are fully vested and can be exercised at any time. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:12 UTC | Keenova Therapeutics plc MNKTQ · Entity 28960 | Disposition to issuerOrdinary Shares | 23,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-119110 · tm2330745-4_4seq1.xml · nonDerivative · entry 1 El-Dada Riad Hussein · CIK 0001926018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On August 28, 2023, Mallinckrodt plc (the "Company") and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On September 20, 2023, the Company's directors presented a petition before the High Court of Ireland (the "Irish High Court") seeking the appointment of an examiner (the "Examiner") to the Company, thereby commencing examinership proceedings with respect to the Company in Ireland. F2 · kind: On October 10, 2023, the Bankruptcy Court entered an order confirming the First Amended Prepackaged Joint Chapter 11 Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates (as may be amended or supplemented from time to time in accordance with its terms, the "Plan"). On November 10, 2023, the Irish High Court made an order confirming a scheme of arrangement proposed by the Examiner that is based on and consistent in all respects with the Plan (the "Scheme"). On November 14, 2023 (the "Effective Date"), the Plan and the Scheme became effective and the Company emerged from bankruptcy. F3 · kind: On the Effective Date, all of the Company's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such Ordinary Shares, were cancelled and extinguished pursuant to the Plan and the Scheme. In connection with emergence, the reporting person ceased to be a Section 16 reporting person. This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014. Read SEC document |
| June 16, 2023 Filed Jun 29, 2023 22:51 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Disposition to issuerOrdinary Shares | 26,277 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-076468 · tm2320181-2_4seq1.xml · nonDerivative · entry 2 El-Dada Riad Hussein · CIK 0001926018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,122 F1 · shares: The restricted stock units (the "RSUs") granted to the reporting person on January 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc ("Mallinckrodt") in connection with the Board of Directors (the "Board") of Mallinckrodt's approval of changes to the compensation of non-employee members of the Board (such changes, the "Compensation Changes"). In connection with the Compensation Changes, and in consideration of the cancelation of the RSUs, the reporting person will receive (i) in the event of a bankruptcy filing, additional cash compensation for 2023 of $210,000 or (ii) in the absence of a bankruptcy filing, additional cash compensation for 2023 of $245,000. In either event, the amounts are to be prepaid pro rata on a quarterly basis and paid in arrears for the prior quarters of fiscal year 2023. F1 · price: The restricted stock units (the "RSUs") granted to the reporting person on January 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc ("Mallinckrodt") in connection with the Board of Directors (the "Board") of Mallinckrodt's approval of changes to the compensation of non-employee members of the Board (such changes, the "Compensation Changes"). In connection with the Compensation Changes, and in consideration of the cancelation of the RSUs, the reporting person will receive (i) in the event of a bankruptcy filing, additional cash compensation for 2023 of $210,000 or (ii) in the absence of a bankruptcy filing, additional cash compensation for 2023 of $245,000. In either event, the amounts are to be prepaid pro rata on a quarterly basis and paid in arrears for the prior quarters of fiscal year 2023. F1 · balance_after: The restricted stock units (the "RSUs") granted to the reporting person on January 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc ("Mallinckrodt") in connection with the Board of Directors (the "Board") of Mallinckrodt's approval of changes to the compensation of non-employee members of the Board (such changes, the "Compensation Changes"). In connection with the Compensation Changes, and in consideration of the cancelation of the RSUs, the reporting person will receive (i) in the event of a bankruptcy filing, additional cash compensation for 2023 of $210,000 or (ii) in the absence of a bankruptcy filing, additional cash compensation for 2023 of $245,000. In either event, the amounts are to be prepaid pro rata on a quarterly basis and paid in arrears for the prior quarters of fiscal year 2023. Read SEC document |
| June 16, 2023 Filed Jun 29, 2023 22:51 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 3,154 | $1.28 | $4,037.12 |
DisclosureSEC source: 0001104659-23-076468 · tm2320181-2_4seq1.xml · nonDerivative · entry 1 El-Dada Riad Hussein · CIK 0001926018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,399 Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:00 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 26,277 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001540 · tm231710-2_4seq1.xml · nonDerivative · entry 1 El-Dada Riad Hussein · CIK 0001926018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,553 F1 · shares: The reported ordinary shares represent restricted stock units ("RSUs"), which will be settled in an equal number of MNK ordinary shares and will vest ratably on each of the first two anniversaries of MNK's emergence from Chapter 11 proceedings on June 16, 2022. F2 · balance_after: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 26,277 newly awarded RSUs and 26,276 RSUs previously reported in Table II. Read SEC document |
| August 16, 2022 Filed Sep 15, 2022 01:15 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | Disposition to issuerRestricted Stock Units · Derivative | 22,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-100150 · tm2225913-3_4seq1.xml · derivative · entry 1 El-Dada Riad Hussein · CIK 0001926018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,276 Underlying: Ordinary Shares · 22,533 shares Expires not disclosed F1 · derivative.exercise_price: (1) As previously disclosed, on August 16, 2022, Riad H. El-Dada agreed to relinquish 22,533 of the restricted stock units ("RSUs") which were previously granted to him on July 1, 2022, with relinquishment to be applied ratably across both vesting tranches of such award, to remedy ministerial errors in computation and to correct for the fact that the RSU grant may have as a technical matter exceeded the applicable annual grant maximum amount set forth in the Mallinckrodt Pharmaceuticals 2022 Stock and Incentive Plan (the "MIP"). Mallinckrodt plc ("Mallinckrodt") has agreed that, as soon as reasonably practical following January 1, 2023, Mallinckrodt will grant to Mr. El-Dada 26,277 RSUs, subject to his continued service through such date and the MIP grant value limit, which will vest ratably on each of the first two anniversaries of emergence. F1 · derivative.exercise_date: (1) As previously disclosed, on August 16, 2022, Riad H. El-Dada agreed to relinquish 22,533 of the restricted stock units ("RSUs") which were previously granted to him on July 1, 2022, with relinquishment to be applied ratably across both vesting tranches of such award, to remedy ministerial errors in computation and to correct for the fact that the RSU grant may have as a technical matter exceeded the applicable annual grant maximum amount set forth in the Mallinckrodt Pharmaceuticals 2022 Stock and Incentive Plan (the "MIP"). Mallinckrodt plc ("Mallinckrodt") has agreed that, as soon as reasonably practical following January 1, 2023, Mallinckrodt will grant to Mr. El-Dada 26,277 RSUs, subject to his continued service through such date and the MIP grant value limit, which will vest ratably on each of the first two anniversaries of emergence. F1 · derivative.expiration_date: (1) As previously disclosed, on August 16, 2022, Riad H. El-Dada agreed to relinquish 22,533 of the restricted stock units ("RSUs") which were previously granted to him on July 1, 2022, with relinquishment to be applied ratably across both vesting tranches of such award, to remedy ministerial errors in computation and to correct for the fact that the RSU grant may have as a technical matter exceeded the applicable annual grant maximum amount set forth in the Mallinckrodt Pharmaceuticals 2022 Stock and Incentive Plan (the "MIP"). Mallinckrodt plc ("Mallinckrodt") has agreed that, as soon as reasonably practical following January 1, 2023, Mallinckrodt will grant to Mr. El-Dada 26,277 RSUs, subject to his continued service through such date and the MIP grant value limit, which will vest ratably on each of the first two anniversaries of emergence. Read SEC document |
| July 01, 2022 Filed Jul 7, 2022 01:11 UTC | Keenova Therapeutics plc MNKPF · Entity 28960 | GrantRestricted Stock Units · Derivative | 48,809 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-025535 · doc4.xml · derivative · entry 1 El-Dada Riad Hussein · CIK 0001926018 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,809 Underlying: Ordinary Shares · 48,809 shares Expires not disclosed F1 · derivative.exercise_price: The grant of restricted stock units vests in equal installments on each of the first and second anniversaries of the date of Mallinckrodt plc's emergence from bankruptcy (June 16, 2022). Each restricted stock unit represents one Ordinary Share, and may be redeemed in either cash or stock. F1 · derivative.exercise_date: The grant of restricted stock units vests in equal installments on each of the first and second anniversaries of the date of Mallinckrodt plc's emergence from bankruptcy (June 16, 2022). Each restricted stock unit represents one Ordinary Share, and may be redeemed in either cash or stock. F1 · derivative.expiration_date: The grant of restricted stock units vests in equal installments on each of the first and second anniversaries of the date of Mallinckrodt plc's emergence from bankruptcy (June 16, 2022). Each restricted stock unit represents one Ordinary Share, and may be redeemed in either cash or stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.